This year, more than 2 million people in the United States are expected to be diagnosed with some form of cancer, according to the American Cancer Society. Nevertheless, screenings, early detection and pinpoint therapies have improved patients’ odds, reducing deaths from many cancers, particularly of the breast, lung and prostate. From 2013 to 2022, the overall death […]
This year, more than 2 million people in the United States are expected to be diagnosed with some form of cancer, according to the American Cancer…
Christopher Weight, MD, Director of Urologic Oncology at Cleveland Clinic joins the Cancer Advances podcast to discuss using artificial intelligence to predict prostate cancer outcomes…
Christopher Weight, MD, Director of Urologic Oncology at Cleveland Clinic joins the Cancer Advances podcast to discuss using artificial intelligence to predict prostate cancer outcomes…
In this installment of The ASCO Post’s Living a Full Life series, Stephen R. Grobmyer, MD, FACS, speaks about his clinical and research career in…
Register for Cleveland Clinic’s 8th Annual Cleveland Breast Cancer Summit: Collaborating for a Cure, Friday August 9, 2024 LIVE at the Intercontinental Hotel & Conference…
When employees are satisfied in their work environment, the results speak for themselves. Newsweek and Plant-A Insights Group present America’s Greatest Workplaces 2025, recognizing companies…
Taletrectinib, an experimental oral next-generation tyrosine kinase inhibitor (TKI), has demonstrated robust clinical activity in the treatment of ROS1-positive non-small cell lung cancer (NSCLC).
Listen as Dr. Kim explains how the model uses common clinical variables to flag high-risk patients who may benefit from endoscopic screening.
The advent of next-generation antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd), has transformed our understanding of human epidermal growth factor receptor 2 (HER2) targetability for…
